Ogivri Injection and Rinvoq
Determining the interaction of Ogivri Injection and Rinvoq and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR CLOSELY: Coadministration of upadacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients receiving upadacitinib, most of whom were taking concomitant immunosuppressants such as methotrexate or corticosteroids. The most common serious infections reported with upadacitinib treatment include pneumonia and cellulitis. Opportunistic infections include tuberculosis, multidermatomal herpes zoster, oral/esophageal candidiasis, and cryptococcosis. Lymphoma and other malignancies have also been observed with upadacitinib use, with or without concomitant immunosuppressants. MANAGEMENT: Close monitoring for the development of infection is recommended if upadacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and upadacitinib dosage adjusted as necessary in accordance with the product labeling. Patients should be advised to contact their physician if they develop signs or symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, or pain or burning during urination. If a serious or opportunistic infection develops, upadacitinib should be interrupted until the infection is controlled. References "Product Information. Rinvoq (upadacitinib)." AbbVie US LLC, North Chicago, IL.
Professional:MONITOR CLOSELY: Coadministration of upadacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients receiving upadacitinib, most of whom were taking concomitant immunosuppressants such as methotrexate or corticosteroids. The most common serious infections reported with upadacitinib treatment include pneumonia and cellulitis. Opportunistic infections include tuberculosis, multidermatomal herpes zoster, oral/esophageal candidiasis, and cryptococcosis. Lymphoma and other malignancies have also been observed with upadacitinib use, with or without concomitant immunosuppressants.
MANAGEMENT: Close monitoring for the development of infection is recommended if upadacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and upadacitinib dosage adjusted as necessary in accordance with the product labeling. Patients should be advised to contact their physician if they develop signs or symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, or pain or burning during urination. If a serious or opportunistic infection develops, upadacitinib should be interrupted until the infection is controlled.
- "Product Information. Rinvoq (upadacitinib)." AbbVie US LLC, North Chicago, IL.
Generic Name: trastuzumab
Brand name: Herceptin, Kanjinti, Ogivri
Synonyms: Ogivri
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Ogivri Injection-Riociguat
- Ogivri Injection-Riomet
- Ogivri Injection-Riomet Oral Suspension
- Ogivri Injection-Risankizumab
- Ogivri Injection-Risankizumab-rzaa topical
- Ogivri Injection-Risedronate
- Rinvoq-Ogivri Intravenous
- Rinvoq-Ohm Allergy Relief
- Rinvoq-Olanzapine
- Rinvoq-Olanzapine and Fluoxetine
- Rinvoq-Olanzapine and Fluoxetine Capsules
- Rinvoq-Olanzapine Extended-Release Injection